Clinical Trial: Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07892794) titled 'Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis' on Oct. 12.

Brief Summary: Pneumonia is a lung infection that can cause serious complications, especially when accompanied by sepsis. Sepsis can trigger excessive inflammation and abnormal blood clotting, potentially leading to organ damage and delayed recovery. Two blood markers, D-dimer and interleukin-6 (IL-6), may increase in patients with these conditions.

Lumbrokinase DLBS1033 (Disolf(R)) is an oral treatment derived from the earthworm Lumbricus rubellus. It has properties that may help break down fibrin, a...